Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPTOP: Nivolumab, Ipilimumab, Gemcitabine, Nab-paclitaxel and SBRT in Pancreatic Cancer
NCT04247165Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Jun 2020
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Herlev Hospital. Started Jun 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04247165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247165.